Key facts
- This page summarizes Daniel Lang's Form 4 filing for Athenex, Inc..
- 1 reported transaction and 4 derivative rows are listed below.
- Accepted by SEC: 21 Jul 2022, 17:28.
Daniel Lang - 20 Jul 2022 Form 4 Insider Report for Athenex, Inc.
- Reporting relationship
- Pres Cell Therapy, VP Corp Dev
- Issuer ticker
- N/A
- Reported as of
- 20 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2022, 17:28:27 UTC
- Prior SEC filing
- 01 Dec 2021
- Next SEC filing
- 19 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/Steven Adams, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Lang filed Form 4 for Athenex, Inc. on 21 Jul 2022.
Change
- Previous filing in this sequence was filed on 01 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATNXQ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 73,413
- Date
- 20 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATNXQ
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 20 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $0.6655
- Footnotes
- F6
ATNXQ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 40,000
- Date
- 20 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $10.25
- Footnotes
- F2
ATNXQ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 50,000
- Date
- 20 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $2.77
- Footnotes
- F3
ATNXQ
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 50,000
- Date
- 20 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Includes 30,000 shares subject to a restricted stock award vesting in four equal annual installments beginning on August 26, 2020.
Footnote F2
This option vests in four equal annual installments beginning on August 27, 2021.
Footnote F3
This option vests in four equal annual installments beginning on September 16, 2022.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of stock.
Footnote F5
The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
Footnote F6
This option vests in four equal annual installments beginning on July 20, 2023.